Pfizer says its vaccine is safe & effective in 5-11 year-olds: 5 things to know

1. The data comes from a phase 2/3 study that included 2,268 participants ages 5-11.
2. The trial participants received two 10-microgram doses of Pfizer’s COVID-19 vaccine, administered 21 days apart. For people ages 12 and older, Pfizer uses a 30-microgram dose.
3. Pfizer said the trial demonstrated a “favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age.” The findings have not been peer reviewed or published in a scientific journal.
4. Pfizer said it will share this data with the FDA and other regulators as soon as possible.
5. Of the drugmakers with a COVID-19 vaccine in use in the U.S., Pfizer is the first one to produce results from a trial testing its vaccine in children ages 5 to 11.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit